Manufacturers Unable to Make Minor Changes to Products in China
This article was originally published in The Gold Sheet
Executive Summary
A lack of a reporting mechanism for minor or moderate changes to approved pharmaceuticals in China makes it difficult for pharmaceutical manufacturers to make lifecycle improvements to products marketed there. Long review timelines and unclear expectations during inspections further complicate the picture.